News & analysis on the clinical development and manufacture of large molecule drugs
Aruvant, Joseph McIntosh
By Ben Hargreaves
- Last updated on
Aruvant Sciences brings in Joseph McIntosh from PTC Therapeutics to take the lead on the development of the biotech’s gene therapy, ARU-1801.
McIntosh joins the team at Aruvant as chief medical officer, after having previously held the role of head of clinical development at PTC Therapeutics.
During the time at his prior role, McIntosh worked across a portfolio of treatments that includes two gene therapies. He has also specialized in rare disease for over a decade, which includes periods working at Shire and Eisai.
Aruvant was launched at the end of 2018 by Roivant, with its lead gene therapy candidate AR-1801 as a core part of its portfolio. The investigational therapy is a potential treatment for sickle cell disease and β-thalassemia.
The treatment is currently undergoing Phase I/II clinical studies, with Aruvant suggesting that preliminary data demonstrates ‘durable reductions’ in disease burden.